0001193125-22-275811.txt : 20221206 0001193125-22-275811.hdr.sgml : 20221206 20221102160100 ACCESSION NUMBER: 0001193125-22-275811 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20221102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aadi Bioscience, Inc. CENTRAL INDEX KEY: 0001422142 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 611547850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 17383 SUNSET AVENUE STREET 2: SUITE A250 CITY: PACIFIC PALISADES STATE: CA ZIP: 90272 BUSINESS PHONE: 424-473-8055 MAIL ADDRESS: STREET 1: 17383 SUNSET AVENUE STREET 2: SUITE A250 CITY: PACIFIC PALISADES STATE: CA ZIP: 90272 FORMER COMPANY: FORMER CONFORMED NAME: Aerpio Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20170316 FORMER COMPANY: FORMER CONFORMED NAME: ZETA ACQUISITION CORP II DATE OF NAME CHANGE: 20071227 CORRESP 1 filename1.htm CORRESP

November 2, 2022

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, DC 20549-3720

Attention:     Jason Drory

 Re:     Aadi Bioscience, Inc.

  Registration Statement on Form S-3

  File No. 333-268021

  Acceleration Request

Requested Date:     November 4, 2022

Requested Time:    4:00 P.M. Eastern Time

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Aadi Bioscience, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-268021) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Dan Koeppen at (858) 350-2393 or via email at dkoeppen@wsgr.com.

[Signature page follows]

Securities and Exchange Commission

November 2, 2022

Page 2

 

Sincerely,

AADI BIOSCIENCE, INC.

/s/ Neil Desai

Neil Desai

President and Chief Executive Officer

 

cc:

Dan Koeppen, Wilson Sonsini Goodrich & Rosati, P.C.

Robert L. Wernli, Jr., Wilson Sonsini Goodrich & Rosati, P.C.

David G. Sharon, Wilson Sonsini Goodrich & Rosati, P.C.